PRPH · ProPhase Labs, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s plans do not alleviate this substantial doubt.”View the 10-Q filed Jun 30, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Dec 22, 2025; bars on opposite sides are not compared.
The closing range begins at the captured split on Dec 22, 2025.
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PRPH
this stock
ProPhase Labs, Inc.
|
$560,641 | -93.3% | -35.8% | — | 0.4% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.52B | +1.0% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$141.79B | -11.5% | +8.5% | 35.8 | 1.7% |
|
NTRA
Natera, Inc.
|
$44.67B | +37.1% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$43.02B | -19.3% | +10.4% | 38.4 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- 0 sh
- Top holder
- Farther Finance Advisors,…
Performance
Raw-price comparisons begin at the captured split on Dec 22, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PRPH | -39.8% | -57.1% | -80.0% | -25.0% | -93.3% |
| SPY | -0.1% | +4.1% | +12.4% | +3.4% | +13.3% |
| vs SPY | -39.7% | -61.3% | -92.4% | -28.4% | -106.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.